|Dr. Xiaochun Xu M.B.A., Ph.D.||Chairman, CEO & Pres||460k||N/A||1971|
|Mr. Jeff Cauble||Principal Financial & Accounting Officer||160k||N/A||1973|
|Mr. James Xu J.D., L.L.M., M.B.A.||Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec.||60k||N/A||1971|
|Mr. Philip H. Coelho||Chief Technology Officer||N/A||N/A||1944|
|Ms. Haihong Zhu||Pres of ThermoGenesis||N/A||N/A||N/A|
Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables. The company is also developing autologous stem cell-based therapeutics that address medical needs for applications in the vascular, cardiology, and orthopedic markets. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.
ThermoGenesis Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.